Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFR. Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck.
Figure 1 EGFR signal transduction and effects of EGFR inhibition on downstream targets.
Scheme of EGFR signal transduction. Nimotuzumab and PD153035 are inhibitors of EGFR: Activation of EGFR results in activation of Akt signaling which relieves a TSC1/TSC2 as well as PRAS40 (via phosphorylation of Thr246)-mediated inhibition of mTORC1. RPS6 phosphorylation at Ser235/236 and Ser 240/244 is regulated by mTORC1.
Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.
Figure 2 EGFR signal transduction and effects of EGFR inhibition on downstream targets.
LNT-229 cells were incubated in serum-free DMEM for 90 min with vehicle (DMSO control), PD153035 (dissolved in DMSO), control solution for nimotuzumab (placebo solution of the trial) or 1 ?M nimotuzumab as indicated. Cellular lysates were analyzed by immunoblot with antibodies as indicated.
Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-EGFR ADCC Recombinant Antibody (Nimotuzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFR. Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-020 | Anti-Human EGFR Recombinant Antibody (Panitumumab) | ELISA, IP, FC, FuncS, Neut, IF, ICC | IgG2 - kappa |
PABX-053 | Recombinant Human Anti-EGFR Antibody (DL11) | WB, ELISA, FuncS | IgG |
PABX-052-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (Nimotuzumab) | WB, ELISA, FuncS | scFv |
PABX-053-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (DL11) | WB, ELISA, FuncS | scFv |
PABX-053-F (E) | Recombinant Human Anti-EGFR Antibody Fab Fragment (DL11) | WB, ELISA, FuncS | Fab |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-710, RRID: AB_3111988)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.